Paclitaxel/Carboplatin
PreclinicalSmall molecule
Paclitaxel/Carboplatin is one of 91 small molecule programs targeting Advanced Solid Tumors. It is currently in Preclinical.
3
Indications
10
Total Trials
3
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Solid Tumor
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Nubeqa
BayerPreclinical
DATROWAY
Daiichi SankyoPreclinical
Fludara
SanofiPreclinical
Zejula
GGlaxo Dba Glaxosmithkline
Preclinical
Augtyro
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Proleukin
IIovance Biotherapeutics, Inc.
Preclinical
Epivir
GGlaxo Dba Glaxosmithkline
Preclinical
Carboplatin AUC-5
Merck & Co.Preclinical
Soc
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Carboplatin2 trials
Triple-Negative Breast Cancer1 trial
Intraperitoneal Chemotherapy1 trial
Non-Small Cell Lung Cancer1 trial
Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer
Completed·—·Phase 2·NCT01196234·84 enrolled
4 more indications
Endometrial Carcinoma1 trial
Locally Advanced1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Paclitaxel/Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCTI BioPharma